title: [New aspects of macrolides: contribution of roxithromycin].
abstract: Roxithromycin (RU 28965) is a new semi-synthetic derivative of erythromycin. Its antibacterial activity is of the same order as that of other macrolides, although its MIC's against Legionella pneumophila are lower. In double-blind comparative studies there was no significant difference in therapeutic effectiveness between roxithromycin and the reference antibiotics tested. However, this new macrolide exhibits exceptional pharmacological properties (prolonged half-life, excellent tissue penetration and intracellular activity), and it is very well tolerated both clinically and biochemically.
authors.affiliation: Clinique des maladies infectieuses A, Montpellier.
authors.forename: A
authors.initials: A
authors.lastname: Bertrand
authors.forename: O
authors.initials: O
authors.lastname: Jonquet
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy*; D055598:Chemical Phenomena; D002621:Chemistry; D006801:Humans; D007933:Leucomycins / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D007933:Leucomycins
vernacular_title: Aspects nouveaux des macrolides: apport de la roxithromycine.